Rob Quinn to join BenevolentAI as Chief Financial Officer
Rob Quinn to join BenevolentAI as Chief Financial Officer to guide the company's growth and financial direction.
NIAID releases additional data validating BenevolentAI’s hypothesis for baricitinib as a treatment for COVID-19 patients in large-scale randomised control trial
Additional data from the ACTT-2 randomised control trial shows reduced time to recovery and improved clinical outcomes for patients with COVID-19.
BenevolentAI welcomes Professor Russ Altman as scientific advisor
As a scientific advisor at BenevolentAI, Professor Russ Altman will help our scientists to further push the boundaries of machine learning applied drug discovery.
BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial
NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.
What we do
Data Diversity initiative
Company Registration: 09781806
Terms & Conditions
Privacy & Cookies Policy
WHAT we do
Why it matters